Funding Arrangements	6 Months Ended
Jun. 30, 2023
Funding Arrangements [Abstract]
Funding Arrangements	Note 4. Funding Arrangements NIAID Contract In September 2022, the Company received a cost-reimbursement contract award from the NIAID (“NIAID Agreement”) to support preclinical, Phase 1 studies and other activities to enable the advancement of epetraborole into late-stage development for acute systemic melioidosis and other biothreat pathogens. The Company can receive up to $17.8 million in funding over a total term of up to 48 months, consisting of a base period and seven option periods. As of June 30, 2023, funding for an 18-month base period totaling $4.3 million has been committed. The Company did not recognize any income related to the reimbursement of operating expenses under this agreement during the three and six months ended June 30, 2023.

Funding Arrangements

6 Months Ended

Jun. 30, 2023

Note 4. Funding Arrangements

NIAID Contract

In September 2022, the Company received a cost-reimbursement contract award from the NIAID (“NIAID Agreement”) to support preclinical, Phase 1 studies and other activities to enable the advancement of epetraborole into late-stage development for acute systemic melioidosis and other biothreat pathogens. The Company can receive up to $17.8 million in funding over a total term of up to 48 months, consisting of a base period and seven option periods. As of June 30, 2023, funding for an 18-month base period totaling $4.3 million has been committed. The Company did not recognize any income related to the reimbursement of operating expenses under this agreement during the three and six months ended June 30, 2023.